The Latest Hepatology Medical Journal Articles

Keep up to date with the latest in hepatology as a sub-specialty of gastroenterology. Check out the latest hepatology articles from leading medical journals in a single view, helping you discover relevant articles quickly and easily.

• Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease.9th June 2021
  Approximately 5% of individuals infected with hepatitis B virus (HBV) are coinfected with hepatitis D virus (HDV). Chronic HBV/HDV coinfection is associated with an unfavourable outcome, with many patients developing liver cirrhosis, liver failure and eventually hepatocellular carcinoma within 5-10 years. The identification of the HBV/HDV receptor and the development of novel in vitro and […]
• Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.4th June 2021
  Hepatocellular carcinoma is the third-leading cause of cancer-related death worldwide. Preservation of health-related quality of life (HRQOL) during treatment is an important therapeutic goal. The aim of this study was to evaluate the effect of treatment with lenvatinib versus sorafenib on HRQOL.REFLECT was a previously published multicentre, randomised, open-label, non-inferiority phase 3 study comparing the […]
• Long-Lasting Dissociation of Esophageal Eosinophilia and Symptoms Following Dilation in Adults with Eosinophilic Esophagitis.1st June 2021
  Esophageal dilation improves dysphagia but not inflammation in eosinophilic esophagitis (EoE) patients. We investigated if dilation modifies the association between symptoms and esophageal eosinophil count (eos/hpf).Adults enrolled in a multisite, prospective Consortium of Gastrointestinal Eosinophilic Disease Researchers OMEGA observational study (NCT02523118) completed the symptom-based EoE activity index (EEsAI) patient-reported outcome instrument and underwent endoscopy with […]
• Long-Lasting Dissociation of Esophageal Eosinophilia and Symptoms Following Dilation in Adults with Eosinophilic Esophagitis.1st June 2021
  Esophageal dilation improves dysphagia but not inflammation in eosinophilic esophagitis (EoE) patients. We investigated if dilation modifies the association between symptoms and esophageal eosinophil count (eos/hpf).Adults enrolled in a multisite, prospective Consortium of Gastrointestinal Eosinophilic Disease Researchers OMEGA observational study (NCT02523118) completed the symptom-based EoE activity index (EEsAI) patient-reported outcome instrument and underwent endoscopy with […]
• Early liver transplantation for acute alcoholic hepatitis: we can’t say no.31st May 2021
  In patients with severe alcoholic hepatitis not responding to medical therapy, it is detrimental to postpone the decision to list a patient in this context of therapeutic dead end. The last decade has seen the place of early transplantation in the therapeutic arsenal in patients with severe alcoholic hepatitis using a restricted selection process of […]
• Psychiatric comorbidities are highly prevalent in non-esophageal eosinophilic gastrointestinal diseases.31st May 2021
  The prevalence of psychiatric comorbidity in non-esophageal eosinophilic gastrointestinal disorders (EGIDs) has not been studied. We aimed to ascertain the prevalence of psychiatric diagnoses and psychiatric medication use in children, adolescents, and adults with EGIDs and to assess whether psychiatric comorbidity affects clinical presentation.This was a retrospective cohort study of newly diagnosed patients with a […]
• Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma.30th May 2021
  Sorafenib has been the standard of care for patients with advanced hepatocellular carcinoma and although immunotherapeutic approaches are now challenging this position, it retains an advantage in HCV seropositive patients. We aimed to quantify the rate of tumour progression in patients receiving sorafenib and relate this figure to survival, both overall, and according to viral […]
• Coexpression gene network analysis reveals novel regulatory pathways involved in porto-sinusoidal vascular disease.30th May 2021
  Porto-sinusoidal vascular disease (PSVD) is a rare vascular liver disease of unknown etiology that causes portal hypertension. It usually affects young individuals and shorts live expectancy. The deregulated pathways involved in PSVD development are unknown and therefore we lack curative treatments. The purpose of this study was to better understand the biological pathology of PSVD […]
• Focal Adhesion Kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation.30th May 2021
  Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase upregulated in many tumor types and a promising target for cancer therapy. Here, we elucidated the functional role of FAK in intrahepatic cholangiocarcinoma (iCCA) development and progression.Expression levels and activation status of FAK were determined in human iCCA samples. The functional contribution of FAK to Akt/YAP […]
• GREATER OVERLAP OF ROME IV DISORDERS OF GUT-BRAIN INTERACTIONS LEADS TO INCREASED DISEASE SEVERITY AND POORER QUALITY OF LIFE.30th May 2021
  Conditions such as irritable bowel syndrome (IBS), functional dyspepsia and functional constipation are among the prevalent gastrointestinal disorders classified as disorders of gut brain interaction (DGBI), which can adversely affect the lives of sufferers. This study aimed to assess the degree and consequences of overlapping DGBI in a large population-based global scale.Internet survey data from […]
• CheckMate 040 Cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.29th May 2021
  Patients with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B liver function are often excluded from clinical trials. In previous studies, overall survival for these patients treated with sorafenib was ∼3-5 months; thus, new treatments are needed. Nivolumab, alone or in combination with ipilimumab, is conditionally approved in the United States to treat patients with aHCC […]
• Characteristics and survival of patients with inflammatory bowel disease and post-colonoscopy colorectal cancers.29th May 2021
  Post-colonoscopy colorectal cancers (PCCRCs) account for up to 50% of colorectal cancers (CRCs) in patients with inflammatory bowel disease (IBD). We investigated characteristics of IBD patients with PCCRC and their survival.We identified IBD patients (ulcerative colitis [UC] and Crohn’s Disease [CD]) diagnosed with CRC from 1995 to 2015. We defined PCCRC as diagnosed between 6 […]
• Covalently closed circular DNA: the ultimate therapeutic target for curing Hepatitis B virus infections.29th May 2021
  Current antiviral therapies, such as pegylated interferon alpha and nucleos(t)ide analogs effectively improve the patient’s quality of life. However, they are limited to control the infection but cannot cure infected hepatocytes. Complete HBV cure is hampered due to the lack of therapies that can directly affect the viral minichromosome, covalently closed circular DNA. Efforts currently […]
• Reevaluation of the Cardiovascular Safety Profile of Tegaserod: A Review of the Clinical Data.28th May 2021
  Tegaserod is a 5-HT4 receptor agonist approved for irritable bowel syndrome with constipation in females <65 years without a history of cardiovascular ischemic events.Safety data are presented from two external adjudications from the 2018 Gastrointestinal Drugs Advisory Committee meeting supporting tegaserod’s reintroduction after its voluntary 2007 withdrawal. Withdrawal was based on an internal adjudication using […]
• Tofacitinib for Biologic-Experienced Hospitalized Patients with Acute Severe Ulcerative Colitis: A Retrospective Case-Control Study.28th May 2021
  Despite rescue therapy, more than 30% of patients with acute severe ulcerative colitis (ASUC) require colectomy. Tofacitinib is a rapidly acting JAK inhibitor with proven efficacy in ulcerative colitis. Tofacitinib may provide additional means for preventing colectomy in patients with ASUC.A retrospective case-control study was performed evaluating the efficacy of tofacitinib induction in biologic-experienced patients […]
• New clinical and pathophysiological perspectives defining the trajectory of cirrhosis.27th May 2021
  Traditionally, the complications of cirrhosis, namely variceal bleeding, ascites and hepatic encephalopathy, were thought to result predominantly from circulatory dysfunction and altered organ perfusion arising as a result of portal hypertension. Over the past 20 years, large, international prospective studies have indicated the importance of systemic inflammation and organ immunopathology as additional determinants of organ […]
• Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction.27th May 2021
  Patients with acutely decompensated cirrhosis have a dismal prognosis and frequently progress to acute-on-chronic liver failure, which is characterised by hepatic and extrahepatic organ failure(s). The pathomechanisms involved in decompensation and disease progression are still not well understood, and as specific disease-modifying treatments do not exist, research to identify novel therapeutic targets is of the […]
• Sarcopenia and frailty in decompensated cirrhosis.27th May 2021
  In patients with decompensated cirrhosis, sarcopenia and frailty are prevalent. Although several definitions exist for these terms, in the field of hepatology, sarcopenia has commonly been defined as loss of muscle mass, and frailty has been broadly defined as the phenotypic manifestation of the loss of muscle function. Prompt recognition and accurate assessment of these […]
• The global burden of cirrhosis: A review of disability-adjusted life-years lost and unmet needs.27th May 2021
  Cirrhosis is a burden on the individual and on public health. The World Health Organization’s metric of public health burden is the disability-adjusted life-year (DALY), the sum of years of life lost due to premature death and years of life lived with disability. The more DALYs attributable to a disease, the greater its burden on […]
• The microbiota in cirrhosis and its role in hepatic decompensation.27th May 2021
  Cirrhosis – the common end-stage of chronic liver disease – is associated with a cascade of events, of which intestinal bacterial overgrowth and dysbiosis are central. Bacterial toxins entering the portal or systemic circulation can directly cause hepatocyte death, while dysbiosis also affects gut barrier function and increases bacterial translocation, leading to infections, systemic inflammation […]
• The multifactorial mechanisms of bacterial infection in decompensated cirrhosis.27th May 2021
  Infections, due to a dysfunctional immune response, pose a great risk to patients with decompensated cirrhosis and herald the beginning of the terminal phase of this disease. Infections typically result from breaches in innate immune barriers and inadequate clearance by immune cells. This leads to bacterial and bacterial product translocation to the systemic circulation, which […]
• The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery.27th May 2021
  Patients with decompensated cirrhosis are currently managed through targeted strategies aimed at preventing or treating specific complications. In contrast, a disease-modifying agent should, by definition, be aimed at globally addressing ‘decompensated cirrhosis’. To be defined as a disease-modifying agent in decompensated cirrhosis, interventions need to demonstrate an unequivocal benefit on the course of disease in […]
• Acute-on-chronic liver failure: A distinct clinical syndrome.27th May 2021
  There are different operating definitions for acute-on-chronic liver failure (ACLF) in different geographic regions. Consortia in Western countries have developed definitions that apply to patients with cirrhosis, while consortia in Asia have developed definitions that apply to patients with chronic liver diseases with or without cirrhosis. Investigators of the Chinese and Western Consortia believe that […]
• Transition to decompensation and acute-on-chronic liver failure: Role of predisposing factors and precipitating events.27th May 2021
  The transition from compensated to decompensated cirrhosis results from a complex interplay of predisposing and precipitating factors and represents an inflection point in the probability of a patient surviving. With the progression of cirrhosis, patients accumulate multiple disorders (e.g. altered liver architecture, portal hypertension, local and systemic inflammation, bacterial translocation, gut dysbiosis, kidney vasoconstriction) that […]
• Intensive care management of acute-on-chronic liver failure.27th May 2021
  The syndrome of acute-on-chronic liver failure combines deterioration of liver function in a patient with chronic liver disease, with the development of extrahepatic organ failure and high short-term mortality. Its successful management demands a rapid and coherent response to the development of dysfunction and failure of multiple organ systems in an intensive care unit setting. […]
• Limitations of current liver donor allocation systems and the impact of newer indications for liver transplantation.27th May 2021
  Liver transplantation represents a life-saving treatment for patients with decompensated cirrhosis, a severe condition associated with a high risk of waiting list mortality. When decompensation occurs rapidly in the presence of extrahepatic organ failures, the condition is called acute-on-chronic liver failure, which is associated with an even higher risk of death, though liver transplantation can […]
• Management of bacterial and fungal infections in cirrhosis: The MDRO challenge.27th May 2021
  Bacterial infections are frequent in cirrhotic patients with acute decompensation or acute-on-chronic liver failure and can complicate the clinical course. Delayed diagnosis and inappropriate empirical treatments are associated with poor prognosis and increased mortality. Fungal infections are much less frequent, usually nosocomial and associated with extremely high short-term mortality. Early diagnosis and adequate empirical treatment […]
• Management of the major complications of cirrhosis: Beyond guidelines.27th May 2021
  Along with a growing understanding of the pathophysiology of cirrhosis and its complications, new therapies and management strategies have emerged in recent years. Many of these advances have helped inform the current EASL clinical practice guidelines1 on the management of some of the key complications of cirrhosis, such as ascites, variceal bleeding and infection. However, […]
• Cancer Risk in 47,241 Individuals with Celiac Disease – A Nationwide Cohort Study.25th May 2021
  Celiac disease (CD) is associated with increased mortality, in part due to cancer. Most studies investigating this cancer risk involved patients diagnosed before widespread increases in CD diagnosis rates and access to gluten-free food. We performed a population-based study of the risk of cancer in CD.We identified all patients in Sweden with CD as defined […]
• Differential clinical characteristics and mortality outcomes in persons with NAFLD and/or MAFLD.25th May 2021
  Metabolic dysfunction-associated fatty liver disease (MAFLD) establishes new criteria for diagnosing fatty liver disease independent of alcohol intake and concomitant viral hepatitis infection. However, the long-term outcomes of patients with MAFLD are sparse. We aimed to describe the characteristics and long-term survival of persons meeting criteria for NAFLD only (non-MAFLD NAFLD), for both NAFLD and […]
• Ileal Pouch Anal Anastomosis for the Management of Ulcerative Colitis is Associated with Significant Disability.25th May 2021
  Disability in patients with medically refractory ulcerative colitis (UC) after total proctocolectomy (TPC) with ileal pouch anal anastomosis (IPAA) is not well understood. The aim of this study was to compare disability in patients with IPAA vs medically managed UC, and identify predictors of disability.This was a multi-center cross-sectional study performed at five academic institutions […]
• An international genome-wide meta-analysis of primary biliary cholangitis: novel risk loci and candidate drugs.25th May 2021
  Primary biliary cholangitis (PBC) is a chronic liver disease in which autoimmune destruction of the small intra-hepatic bile ducts eventually leads to cirrhosis. Many patients have inadequate response to licensed medications, motivating the search for novel therapies. Previous genome-wide association studies (GWAS) and meta-analyses (GWMA) of PBC have identified numerous risk loci for this condition, […]
• Linkage of resistance-associated substitutions in GT1 sofosbuvir+NS5A inhibitor failures treated with glecaprevir/pibrentasvir.23rd May 2021
  Re-treatment with glecaprevir/pibrentasvir (G/P) resulted in >90% SVR12 rate in HCV genotype 1 (GT1) patients who previously failed a regimen of sofosbuvir plus an NS5A inhibitor (NS5Ai). This study investigated the prevalence and impact of baseline NS3 and NS5A resistance-associated substitutions (RASs) on the efficacy of G/P in prior GT1 sofosbuvir+NS5Ai failures and the persistence […]
• Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection.23rd May 2021
  Shortened duration therapy for acute and recent hepatitis C virus (HCV) infection has been shown to be highly effective in several small non-randomised studies with direct-acting antiviral regimens, however large randomised studies are lacking.REACT was an NIH-funded multicentre international, open-label, randomised, phase 4 non-inferiority trial examining the efficacy of short course (6 weeks) versus standard […]
• Effect of Exclusion Diets on Symptom Severity and the Gut Microbiota in Patients with Irritable Bowel Syndrome.22nd May 2021
  Altered fecal microbiota have been reported in IBS, although studies vary which could be due to dietary effects. Many IBS patients may eliminate certain foods because of their symptoms, which in turn may alter fecal microbiota diversity and composition. This study aims were to determine if dietary patterns were associated with IBS, symptoms, and fecal […]
• RNA helicase DDX5 enables STAT1 mRNA translation and interferon signalling in hepatitis B virus replicating hepatocytes.22nd May 2021
  RNA helicase DDX5 is downregulated during HBV replication and poor prognosis HBV-related hepatocellular carcinoma (HCC). The objective of this study is to investigate the role of DDX5 in interferon (IFN) signalling. We provide evidence of a novel mechanism involving DDX5 that enables translation of transcription factor STAT1 mediating the IFN response.Molecular, pharmacological and biophysical assays […]
• Aminotransferases during treatment predict long-term survival in patients with autoimmune hepatitis type 1: a landmark analysis.22nd May 2021
  Biochemical remission, important treatment goal in autoimmune hepatitis (AIH), has been associated with better long-term survival. The aim of this study was to determine the independent prognostic value of aminotransferases and immunoglobulin G (IgG) during treatment on long-term transplant-free survival in AIH.In a multicenter cohort ALT, AST and IgG were collected at diagnosis, 6, 12, […]
• Distinct Clinical Physiologic Phenotypes of Patients with Laryngeal Symptoms Referred for Reflux Evaluation.22nd May 2021
  Heterogeneous presentations and disease mechanisms among patients with laryngeal symptoms account for misdiagnosis of laryngopharyngeal reflux (LPR), variations in testing and suboptimal outcomes. We aimed to derive phenotypes of patients with laryngeal symptoms based on clinical and physiologic data and to compare characteristics across phenotypes.302 adult patients with chronic laryngeal symptoms were prospectively enrolled at […]
• The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease.21st May 2021
  Fatty liver disease associated with metabolic dysfunction is of increasing concern in mainland China, the world’s most populous country. The incidence of fatty liver disease is highest in China, surpassing the incidence in European countries and the USA. An international consensus panel recently published an influential report recommending a novel definition of fatty liver disease […]
• Breaking the therapeutic ceiling in drug development in ulcerative colitis.21st May 2021
  Increased knowledge of the intricate pathogenesis of ulcerative colitis has triggered an advance in drug development during the past two decades, resulting in the advent of several biological agents and small-molecule therapies. Although the increase in therapeutic options is positive, remission rates of patients with ulcerative colitis given new therapeutic agents in induction trials remain […]
• Associations among adipose tissue immunology, inflammation and exosomes and insulin sensitivity in people with obesity and nonalcoholic fatty liver disease.18th May 2021
  Insulin resistance is a key factor in the pathogenesis of NAFLD. We evaluated the importance of subcutaneous abdominal adipose tissue (SAAT) inflammation and both plasma and SAAT-derived exosomes in regulating insulin sensitivity in people with obesity and NAFLD.Adipose tissue inflammation (macrophage and T cell content and expression of proinflammatory cytokines), liver and whole-body insulin sensitivity […]
• Dual and opposing roles of the androgen receptor in VETC-dependent and invasion-dependent metastasis of hepatocellular carcinoma.18th May 2021
  Contradictory roles of the androgen receptor (AR) in hepatocellular carcinoma (HCC) metastasis have been reported. We have shown that VETC (vessels encapsulating tumor clusters) mediates invasion-independent metastasis, whereas VETC- HCCs metastasize in an invasion-dependent manner. Here we aimed to reveal the roles of AR in HCC metastasis.Mouse xenograft models, clinical samples, and cell models were […]
• Significant liver injury during hospitalization for COVID-19 is not associated with liver insufficiency or death.18th May 2021
  COVID-19 is associated with hepatocellular liver injury of uncertain significance. We aimed to determine whether development of significant liver injury during hospitalization is related to concomitant medications or processes common in COVID-19 (e.g. ischemia, hyperinflammatory or hypercoagulable states) and to determine whether it can result in liver failure and death.834 consecutive patients hospitalized with COVID-19 […]
• Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load.18th May 2021
  Loss of serum hepatitis B surface antigen (HBsAg) is a hallmark of spontaneous and therapy induced resolution of HBV infection, since it generally reflects a profound decrease in viral replication. However, integrated HBV DNA can contribute to HBsAg expression independent of viral replication. The relative contributions of these two sources of HBsAg are not well […]
• Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.18th May 2021
  Liver biopsy is still needed for fibrosis staging in many patients with non-alcoholic fatty liver disease. The aims of this study were to evaluate the individual diagnostic performance of liver stiffness measurement by vibration controlled transient elastography (LSM-VCTE), Fibrosis-4 Index (FIB-4) and NAFLD (non-alcoholic fatty liver disease) Fibrosis Score (NFS) and to derive diagnostic strategies […]
• Molecular characterization of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.16th May 2021
  Non-alcoholic steatohepatitis (NASH)-related hepatocellular carcinoma (HCC) is increasing globally, but its molecular features are not well defined. We aimed to identify unique molecular traits characterizing NASH-HCC compared to other HCC aetiologies.We collected 80 NASH-HCC and 125 NASH samples from 5 institutions. Expression array (n=53 NASH-HCC; n=74 NASH) and whole exome sequencing (n=52 NASH-HCC) data were […]
• Optical evaluation for predicting cancer in large non-pedunculated colorectal polyps is accurate for flat lesions.16th May 2021
  The ability of optical evaluation to diagnose submucosal invasive cancer (SMIC) prior to endoscopic resection of large (≥ 20mm) non-pedunculated colorectal polyps (LNPCPs) is critical to inform therapeutic decisions. Prior studies suggest that it is insufficiently accurate to detect SMIC. It is unknown whether lesion morphology influences optical evaluation performance.LNPCPs ≥ 20mm referred for endoscopic […]
• Prognosis of French COVID-19 patients with chronic liver disease: a national retrospective cohort study for 2020.16th May 2021
  There is uncertainty on the risk of dying after coronavirus disease 2019 (Covid-19) in chronic liver disease patients.We explored the outcomes of all Covid-19 adult inpatients in France, in 2020. We computed adjusted odds-ratios to measure the associations between chronic liver disease, alcohol use disorders, mechanical ventilation and day-30, in-hospital, mortality.The sample comprised 259,110 patients […]
• Human and preclinical studies of the host-gut microbiome co-metabolite hippurate as a marker and mediator of metabolic health.12th May 2021
  Gut microbial products are involved in regulation of host metabolism. In human and experimental studies, we explored the potential role of hippurate, a hepatic phase 2 conjugation product of microbial benzoate, as a marker and mediator of metabolic health.In 271 middle-aged non-diabetic Danish individuals, who were stratified on habitual dietary intake, we applied 1H-nuclear magnetic […]
• Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.10th May 2021
  Inhibition of vascular endothelial growth factor receptor (VEGFR) has shown antitumour activity in advanced hepatocellular carcinoma, but few studies of VEGFR inhibitors have been done in populations with a high prevalence of hepatitis B virus infection. The aim of this study was to evaluate the efficacy and safety of apatinib in patients with pretreated advanced […]
• Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study.9th May 2021
  Limited empirical evidence exists for the effectiveness of hepatitis C virus (HCV) treatment-as-prevention. The Surveillance and Treatment of Prisoners with hepatitis C (SToP-C) study aimed to assess the effect of HCV treatment-as-prevention in the prison setting.SToP-C was a prospective study, including a before-and-after analysis, within a cohort of people incarcerated in two maximum-security prisons (male) […]
• Surveillance of patients with cirrhosis remains suboptimal in the United States.9th May 2021
  Regular monitoring/surveillance for liver complications is crucial in the management of patients with cirrhosis to reduce morbidity and mortality. Recommendations from professional societies are available but adherence is not well studied, especially outside of academic centers. We aimed to determine the frequencies and factors associated with laboratory monitoring, hepatocellular carcinoma (HCC) and esophageal varices (EV) […]
• Dysregulation of the ESRP2-NF2-YAP/TAZ axis promotes hepatobiliary carcinogenesis in non-alcoholic fatty liver disease.8th May 2021
  Nonalcoholic Fatty Liver Disease (NAFLD), the hepatic correlate of the metabolic syndrome, is a major risk factor for hepatobiliary cancer (HBC). Although chronic inflammation is thought to be the root cause of all these diseases, the mechanism whereby it promotes HBC in NAFLD remains poorly understood. Here we aim to evaluate the hypothesis that inflammation-related […]
• Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach.7th May 2021
  Non-alcoholic fatty liver disease (NAFLD) is a public health problem worldwide. This narrative Review provides an overview of the current literature to support the notion that NAFLD is a multisystem disease. Convincing evidence shows a strong association between NAFLD and the risk of developing multiple extrahepatic complications such as type 2 diabetes, cardiovascular disease (ie, […]
• Global burden of acute viral hepatitis and its association with socioeconomic development status, 1990-2019.7th May 2021
  Acute viral hepatitis (AVH) represents an important global health problem; however, the progress in understanding AVH is limited because of the priority of combating persistent hepatitis B (HBV) and C (HCV) virus infections. Therefore, an improved understanding of the burden of AVH is required to help design strategies for global intervention.Data of four major AVH […]
• Glutaminolysis-induced mTORC1 activation drives non-alcoholic steatohepatitis progression.7th May 2021
  A holistic insight on the relationship between obesity and metabolic dysfunction-associated fatty liver disease is an unmet clinical need. Omics investigations can be used to investigate the multifaceted role of altered mitochondrial pathways to promote nonalcoholic steatohepatitis, a major risk factor for liver disease-associated death. There are no specific treatments but remission via surgery might […]
• Resolution of hepatitis E virus infection in CD8+ T cell depleted rhesus macaques.7th May 2021
  HEV is a significant cause of acute hepatitis globally. Some genotypes establish persistent infection when immunity is impaired. Adaptive immune mechanisms that mediate resolution of infection have not been identified. Here, the requirement for CD8+ T cells to control HEV infection was assessed in rhesus macaques, a model of acute and persistent HEV infection in […]
• The times they are a-changing – A refined proposal for finite HBV nucleos(t)ide analog therapy.6th May 2021
  Although discontinuation of nucleos(t)ide analogue (NA) treatment before HBsAg loss is part of all current hepatitis B virus (HBV) treatment guidelines for HBeAg-positive patients who achieved HBeAg seroconversion, a treatment endpoint known to be associated with silencing of HBV transcriptional activity and restoration of HBV-specific immune control, it is still highly controversial whether it is […]
• Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: results of the ELITA/EF-CLIF collaborative study (ECLIS).5th May 2021
  Liver transplantation (LT) has been proposed to be an effective salvage therapy even for the sickest patients with acute-on-chronic liver failure (ACLF). This large collaborative study was designed to address the current clinical practice and outcomes of ACLF patients wait listed (WL) for LT in Europe.Retrospective study including 308 consecutive ACLF patients, listed in 20 […]
• TGF-β signaling in Liver, Pancreas, and Gastrointestinal Diseases and Cancer.3rd May 2021
  Genetic alterations affecting transforming growth factor β (TGF-β) signaling are exceptionally common in diseases and cancers of the gastrointestinal (GI) system. As a regulator of tissue renewal, TGF-β signaling and the downstream SMAD-dependent transcriptional events play complex roles in the transition from a noncancerous disease state to cancer in the GI tract, liver, and pancreas. […]